Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-intensified temozolomide rechallenge in recurrent or progressive glioblastoma
2008-006871-60Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Progression-free survival and Median time to treatment failure. Started Mar 2009; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-006871-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006871-60.